Identification, characterization, and high-performance liquid chromatography quantification of process-related impurities in vonoprazan fumarate

被引:17
作者
Liu, Lei [1 ]
Cao, Na [1 ]
Ma, Xingling [1 ]
Xiong, Kaihe [2 ]
Sun, Lili [2 ]
Zou, Qiaogen [1 ]
机构
[1] Nanjing Tech Univ, Sch Pharmaceut Sci, Nanjing 210009, Jiangsu, Peoples R China
[2] Nanjing Tech Univ, Coll Biotechnol & Pharmaceut Engn, Nanjing 210009, Jiangsu, Peoples R China
关键词
High-performance liquid chromatography; Process-related impurities; Vonoprazan fumarate; COMPETITIVE ACID BLOCKER; DEGRADATION-PRODUCTS; MASS-SPECTROMETRY; TAK-438; HYDROCHLORIDE; SEPARATION; BEHAVIOR;
D O I
10.1002/jssc.201501154
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
High-performance liquid chromatography analysis of vonoprazan fumarate, a novel proton pump inhibitor drug revealed six impurities. These were identified by liquid chromatography with mass spectrometry. Further, the structures of the impurities were confirmed by synthesis followed by characterization by mass spectrometry, NMR spectroscopy, and infrared spectroscopy. On the basis of these data and knowledge of the synthetic scheme of vonoprazan fumarate, the previously unknown impurity was identified as 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methyldimethylamine, which is a new compound. The possible mechanisms by which these impurities were formed were also discussed. A high-performance liquid chromatography method was optimized in order to separate, selectively detect, and quantify all process-related impurities of vonoprazan fumarate. The presented method has been validated in terms of linearity, limits of detection, and quantification, and response factors and, therefore, is highly suitable for routine analysis of vonoprazan fumarate related substances as well as stability studies.
引用
收藏
页码:1232 / 1241
页数:10
相关论文
共 16 条
  • [1] [Anonymous], 2006, Impurities in New Drug Products Q3B (R2)
  • [2] Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)
    Arikawa, Yasuyoshi
    Nishida, Haruyulci
    Kurasawa, Osamu
    Hasuoka, Atsushi
    Hirase, Keizo
    Inatomi, Nobuhiro
    Hori, Yasunobu
    Matsukawa, Jun
    Imanishi, Akio
    Kondo, Mitsuyo
    Tarui, Naoki
    Hamada, Teruki
    Takagi, Terufumi
    Takeuchi, Toshiyuki
    Kajino, Masahiro
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (09) : 4446 - 4456
  • [3] Reversed-phase liquid chromatography with electrospray mass detection and 1H and 13C NMR characterization of new process-related impurities, including forced degradants of Efavirenz: Related substances correlated to the synthetic pathway
    Gadapayale, Kamalesh
    Kakde, Rajendra
    Sarma, V. U. M.
    [J]. JOURNAL OF SEPARATION SCIENCE, 2015, 38 (02) : 218 - 230
  • [4] Geng F., Method for Preparing Vonoprazan Fumarate, Patent No. [104860923A, 104860923]
  • [5] A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals
    Hori, Yasunobu
    Matsukawa, Jun
    Takeuchi, Toshiyuki
    Nishida, Haruyuki
    Kajino, Masahiro
    Inatomi, Nobuhiro
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 337 (03) : 797 - 804
  • [6] ICH Harmonised Tripartite Guidline, 2005, VALIDATION ANAL PROC
  • [7] Ikeda M., Liquid preparations of amines and organic acid stabilized by salts, Patent No. [WO 2014003199A1, 2014003199]
  • [8] Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
    Jenkins, H.
    Sakurai, Y.
    Nishimura, A.
    Okamoto, H.
    Hibberd, M.
    Jenkins, R.
    Yoneyama, T.
    Ashida, K.
    Ogama, Y.
    Warrington, S.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (07) : 636 - 648
  • [9] Kajino M., 1-Heterocyclyl-sulfonyl, 2-aminomethyl, 5-(Hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors, Patent No. [WO 2007026916A1, 2007026916]
  • [10] Kajino M., Proton pump inhibitors, Patent No. [WO 2006036024A1, 2006036024]